Ön Boynuz Motor Nöron Hastalıkları
Özet
Ön boynuz motor nöron hastalıkları, doğumdan yetişkinliğe kadar geniş bir yelpazede ortaya çıkabilen, yürüme, solunum ve yutma gibi temel işlevleri etkileyen heterojen bir klinik tablo grubudur. Bu hastalıkların en sık karşılaşılan tipi olan Spinal Musküler Atrofi (SMA), SMN1 genindeki mutasyonlara bağlı gelişen genetik bir dejenerasyon olup motor nöron kaybı ve kas atrofisi ile karakterizedir. Tedavi yaklaşımlarında gen replasmanı, gen eklenmesini modifiye eden ajanlar ve destekleyici bakım yöntemleri öne çıkarken, erken tanı ve tedaviye hızlı erişim nöronların korunması açısından kritik öneme sahiptir. Hastalığın sınıflandırılması klasik tiplerden fonksiyonel evrelemeye doğru evrilerek, klinik izlem ve tedavi yanıtlarının değerlendirilmesinde daha dinamik bir yaklaşım sunmaktadır.
Anterior horn motor neuron diseases represent a heterogeneous group of conditions manifesting from infancy to adulthood, leading to impairments in walking, breathing, and swallowing. Spinal Muscular Atrophy (SMA), the most prevalent form, is characterized by genetic degeneration caused by SMN1 mutations, resulting in progressive motor neuron loss and muscle atrophy. Therapeutic strategies focus on gene replacement, agents that modify gene splicing, and supportive care, where early diagnosis and prompt treatment initiation are critical for preserving motor neurons. Disease classification is evolving from traditional typologies toward functional staging, providing a more dynamic approach for clinical monitoring and evaluating treatment responses.
Referanslar
Teoh HL, Carey K, Sampaio H, Mowat D, Roscioli T, Farrar M. Inherited paediatric motor neuron disorders: Beyond spinal muscular atrophy. Neural Plast. 2017;2017:1–22.
Garg N, Park SB, Vucic S, et al. Differentiating lower motor neuron syndromes. J Neurol Neurosurg Psychiatry. 2017;88(6):474–83.
Yang ML, Connolly AM, Swaiman KF, Ashwal S. Other Motor Neuron Diseases of Childhood. 6. th. Elsevier; 2018. e2384-2389.
Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. Pract Neurol. 2013;13(3):153–64.
Verschueren A. Motor neuropathies and lower motor neuron syndromes. Rev Neurol (Paris). 2017;173(5):320–5.
Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103–15.
Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era: Spinal Muscular Atrophy. Muscle Nerve. 2015;51(2):157–67.
D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6(1):71.
Darras BT. Spinal muscular atrophies. Pediatr Clin North Am. 2015;62(3):743-66.
Han JJ, McDonald CM. Diagnosis and clinical management of spinal muscular atrophy. Phys Med Rehabil Clin N Am. 2008;19(3):661–80, xii.
Munsat TL, Davies KE. International SMA consortium meeting Neuromuscul Disord. Vol. 2. 1992; 2(5–6):423–8.
Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831–46.
Markowitz JA, Singh P, Darras BT. Spinal muscular atrophy: a clinical and research update. Pediatr Neurol. 2012;46(1):1–12.
Nance JR. Spinal muscular atrophy. Continuum (Minneap Minn). 2020;26(5):1348–68.
Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: Progress and challenges.Neurotherapeutics. 2015;12(2):290–302.
Peeters K, Chamova T, Jordanova A. Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies. Brain. 2014;137(Pt 11):2879–96.
Sugarman EA, Nagan N, Zhu H. Pan-ethic carrier screening and prenatal diagnosis for spinal muscular atrophy: Clinical laboratory analysis of > 72,400 specimens. Eur J Hum Genet. 2012;20(2732).
Dubowitz V. Very severe spinal muscular atrophy (SMAtype 0): an expanding clinical phenotype. Eur J Paediatr Neurol. 1999;3(2).
ZerresK, Rudnik-Schoneborn S, Forkert R, Wirth B. Genetic basis of adult-onset spinal muscular atrophy. Lancet. 1995;346(8983):1162.
Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027–49.
Tizzano EF, Finkel RS. Spinal muscular atrophy: A changing phenotype beyond the clinical trials. Neuromuscul Disord. 2017;27(10):883–9.
Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: From phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet. 2020;21(1):231–61.
Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38–43.
Macleod MJ, Taylor JE, Lunt PW, Mathew CG, Robb SA. Prenatal onset spinal muscular atrophy. Eur J Paediatr Neurol. 1999;3(2):65–72.
Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–65.
Gennarelli M, Lucarelli M, Capon F, et al. Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun. 1995;213(1):342–8.
Helmken C, Hofmann Y, Schoenen F, et al. Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet. 2003;114(1):11–21.
Thelen MP, Kye MJ. The Role of RNA Binding Proteins for Local mRNATranslation: Implications in Neurological Disorders. Front Mol Biosci. 2020;6:1-6.
Jablonka S, Sendtner M. Developmental regulation of SMN expression: pathophysiological implications and perspectives for therapy development in spinal muscular atrophy. Gene Ther. 2017;24(9):506–13.
Schrank B, Götz R, Gunnersen JM, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A. 1997;94(18):9920–5.
Lorson CL, Strasswimmer J, Yao JM, et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet. 1998;19(1):63–6.
Otter S, Grimmler M, Neuenkirchen N, Chari A, Sickmann A, Fischer U. A comprehensive interaction map of the human survival of motor neuron (SMN) complex. J Biol Chem. 2007;282(8):5825–33.
Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 1996;15(14):3555–65.
Zhang Z, Lotti F, Dittmar K, et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell. 2008;133(4):585–600.
Bäumer D, Lee S, Nicholson G, et al. Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy. PLoS Genet. 2009;5(12):e1000773:1-14.
Donlin-Asp PG, Fallini C, Campos J. The Survival of Motor Neuron Protein Acts as a Molecular Chaperonefor mRNP Assembly. Cell Rep. 2017;14;18(7):1660-1673.
Tadesse H, Deschênes-Furry J, Boisvenue S, Côté J. KH-type splicing regulatory protein interacts with survival motor neuron protein and is misregulated in spinal muscular atrophy. Hum Mol Genet. 2008;17(4):506–24.
Akten B, Kye MJ, Hao LT, et al. Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits. Proc Natl Acad Sci U S A. 2011;108(25):10337–42.
Fallini C, Zhang H, Su Y, et al. The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons. J Neurosci. 2011;31(10):3914–25.
Fallini C, Donlin-Asp PG, Rouanet JP, Bassell GJ, Rossoll W. Deficiency of the survival of motor neuron protein impairs mRNA localization and local translation in the growth cone of motor neurons. J Neurosci. 2016;36(13):3811–20.
Rihan K, Antoine E, Maurin T, et al. A new cis-acting motif is required for the axonal SMN-dependent Anxa2 mRNA localization. RNA. 2017;23(6):899–909.
Saal L, Briese M, Kneitz S, Glinka M, Sendtner M. Subcellular transcriptome alterations in a cell culture model of spinal muscular atrophy point to widespread defects in axonal growth and presynaptic differentiation. RNA. 2014;20(11):1789–802.
Donnelly CJ, Park M, Spillane M, et al. Axonally synthesized β-actin and GAP-43 proteins support distinct modes of axonal growth. J Neurosci. 2013;33(8):3311–22.
Lefebvre S, Sarret C. Pathogenesis and therapeutic targets in spinal muscular atrophy (SMA). Arch Pediatr. 2020 Dec;27(7S):7S3-7S8.
Martinez TL, Kong L, Wang X, Osborne MA, Crowder ME, Van Meerbeke JP, et al. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. J Neurosci. 2012;32(25):8703–15.
Boido M, Vercelli A. Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy. Front Neuroanat. 2016;10:6.
Khalil B, Morderer D, Price PL, Liu F, Rossoll W. mRNP assembly, axonal transport, and local translation in neurodegenerative diseases. Brain Res. 2018;1693:75–91.
Goulet B, Kothary R, Parks R. At the “junction” of spinal muscular atrophy pathogenesis: The role of neuromuscular junction dysfunction in SMA disease progression. Curr Mol Med. 2013;13(7):1160–74.
Boyer JG, Deguise M-O, Murray LM, et al. Myogenic program dysregulation is contributory to disease pathogenesis in spinal muscular atrophy. Hum Mol Genet. 2014;23(16):4249–59.
Kim J-K, Jha NN, Feng Z, et al. Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models. J Clin Invest. 2020;130(3):1271–87.
Bertrandy S, Burlet P, Clermont O, et al. The RNA-binding properties of SMN: deletion analysis of the zebrafish orthologue defines domains conserved in evolution. Hum Mol Genet. 1999;8(5):775–82.
Nery FC, Siranosian JJ, Rosales I, et al. Impaired kidney structure and function in spinal muscular atrophy. Neurol Genet. 2019;5(5):e353.
Rudnik-Schöneborn S, Heller R, Berg C, et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet. 2008;45(10):635–8.
Nash LA, Burns JK, Chardon JW, Kothary R, Parks RJ. Spinal muscular atrophy: More than a disease of motor neurons? Curr Mol Med. 2016;16(9):779–92.
Bowerman M, Becker CG, Yáñez-Muñoz RJ, et al. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech. 2017;10(8):943–54.
Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: Mutations, testing, and clinical relevance. Appl Clin Genet. 2021;14:11–25.
Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70(2):358–68.
Hahnen E, Schönling J, Rudnik-Schöneborn S, Zerres K, Wirth B. Hybrid survival motor neuron genes in patients with autosomal recessive spinal muscular atrophy: new insights into molecular mechanisms responsible for the disease. Am J Hum Genet. 1996;59(5):1057–65.
Steege G, Grootscholten PM, Cobben JM, et al. Apparent gene conversions involving the SMN gene in the region of the spinal muscular atrophy locus on chromosome 5. Am J Hum Genet. 1996;59:834–38.
Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15(3):228.
Alías L, Bernal S, Fuentes-Prior P, et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet. 2009;125(1):29–39.
Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15(3):228.
Calucho M, Bernal S, Alías L, et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208–15.
Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A. 2004;130A(3):307–10.
Prior TW, Krainer AR, Hua Y, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85(3):408–13.
Oprea GE, Kröber S, McWhorter ML, et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science. 2008;320(5875):524–7.
Riessland M, Kaczmarek A, Schneider S, et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet. 2017;100(2):297–315.
Hendrickson BC, Donohoe C, Akmaev VR, et al. Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet. 2009;46(9):641–4
Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57(5):704–12.
Jędrzejowska M. Advances in Newborn Screening and Presymptomatic Diagnosis of Spinal Muscular Atrophy. Degener Neurol Neuromuscul Dis. 2020.
Kariyawasam DST, Russell JS, Wiley V, Alexander IE, Farrar MA. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med. 2020;22(3):557–65.
Vill K, Kölbel H, Schwartz O, et al. One year of newborn screening for SMA - results of a German pilot project. J Neuromuscul Dis. 2019;6(4):503–15.
Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145–58.
Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020;7(2):97–100.
Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy -insights and challenges in the treatment era. Nat Rev Neurol. 2020;Dec;16(12):706-715.
Messina S, Sframeli M. New treatments in spinal muscular atrophy: Positive results and new challenges. J Clin Med. 2020;9(7):2222.
Govoni A, Gagliardi D, Comi GP, Corti S. Time is motor neuron: Therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol Neurobiol. 2018;55(8):6307–18.
Cartwright MS, Upadhya S. Selecting disease‐modifying medications in 5q spinal muscular atrophy. Muscle Nerve. 2021;(mus.27358). Epubahead of print. Available from: http://dx.doi.org/10.1002/mus.27358
Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, et al. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20(3):155–61.
Dubowitz L, Dubowitz V, Mercuri E, et al. Hammersmith Neurological Examinations. Available from: https://hammersmith-neuro-exam.com. Accessed December 8, 2020.
Lennon EM, Gardner JM, Karmel BZ, Flory MJ. Bayley scales of infant development. In: Encyclopedia of Infant and Early Childhood Development. Elsevier; 2008. p. 145–56.
Hammersmith Functional Motor Scale Expanded for SMA (HFMSA). Columbiasma.org. Available from: http://columbiasma.org/docs/hfmse_2019_manual.pdf. Accessed December 8, 2020
Mazzone ES, Mayhew A, Ramsey D, et al. Revised upper limb module for SMA (RULM for SMA). http://columbiasma.org/docs/cme-2010/ rulm-generic-manual-16-dec-2014.pdf. Accessed December 8, 2020
Vuillerot C, Payan C, Iwaz J, Ecochard R, Bérard C, MFM Spinal Muscular Atrophy Study Group. Responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch Phys Med Rehabil. 2013;94(8):1555–61.
Rigo F, Hua Y, Krainer AR, Bennett CF. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol. 2012;199(1):21–5.
Finkel RS, Mercuri E, Darras BT. Nusinersen versus Sham Control in Infantile- Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377(1723).
Mercuri E, Darras BT, Chiriboga CA. Nusinersen versus Sham Control in Later- Onset Spinal Muscular Atrophy. N Engl J Med. 2018;378(625).
De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842–856.
Spinraza (nusinersen) injection, for intrathecal use. https://www. accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf. Accessed December 8, 2020.
Hagenacker T, Wurster CD, Günther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317-325.
Kichula EA, Proud CM, Farrar MA, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve [Internet]. 2021;(mus.27363). Available from: http://dx.doi.org/10.1002/mus.27363
Zolgensma (onasemnogene abeparvovec-xioi). Package insert. AveXis, Inc, 2021. https://www.novartis.us/sites/www.novartis.us/files/ zolgensma.pdf. Accessed March 19, 2021
Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–22.
Shell R, Day JW, Chiriboga C. Onasemnogene abeparvovec-xioi gene-replacement therapy for spinal muscular atrophy type 1 (SMA1): Phase 3 US Study (STR1VE) Update (1828. Neurology. 2020;94(1828).
Day JW, Finkel RS, Chiriboga CA, al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284–93.
Results from the ongoing presymptomatic SMA study of zolgensma. https://www.zolgensma.com/clinical-studies/presymptomatic-studyresults. Accessed December 8, 2020.
Feldman AG, Parsons JA, Dutmer CM, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020;225:252-258.e1.
Chand DH, Zaidman C, Arya K, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: A case series. J Pediatr. 2021;231:265–8.
European Medicines Agency. Zolgensma summary of product characteristics Europa.eu. Available from: https://www.ema.europa.eu/ Accessed December 8, 2020.
Poirier A, Weetall M, Heinig K, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018;6(6):e00447.
Baranello G, Servais L, Day JW. FIREFISH Part 1: 1-year results on motor function in babies with type 1 SMA (S25. 003. Neurology. 2019;92(Suppl.):003 29.
Baranello G, Servais L, Masson R, et al. FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA). In: Paediatric respiratory physiology and sleep. European Respiratory Society; 2020.
Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915–23.
Mercuri E, Baranello G, Kirschner J, et al. Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study. In 2019.
Mercuri E, Barisic N, Boespflug-Tanguy O, et al. SUNFISH Part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) (1260). Neurology. 2020;94:1260.
Evrysdi(risdiplam) prescribing information. https://www.accessdata.fda. gov/ drugsatfda_docs/ label/ 2020 /213535s000lbl.pdf Accessed on April 14, 2021.
Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57(5):704–12.
Finkel RS. Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I. Neuromuscul Disord. 2013;23(2):112–5.
Darras BT, Crawford TO, Finkel RS, et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019;6(5):932–44.
Wadman RI, Vrancken AFJE, van den Berg LH, van der Pol WL. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology. 2012;79(20):2050–5.
Khirani S, Dabaj I, Amaddeo A, et al. Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy. Pediatr Neurol. 2017;73:78-87.e1.
Pera MC, Luigetti M, Sivo S, et al. Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? Neuromuscul Disord. 2018;28(10):863–4.
Messina S, Sframeli M, Maggi L, et al. Spinal muscular atrophy: state of the art and new therapeutic strategies. Neurol Sci. 2021; Epubahead of print. Available from: http://dx.doi.org/10.1007/s10072-021-05258-3
Hwee DT, Kennedy A, Ryans J, et al. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014;9(5):e96921.
Long KK, O’Shea KM, Khairallah RJ, et al. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet. 2019;28(7):1076–89.
Markström A, Cohen G, Katz-Salamon M. The effect of long term ventilatory support on hemodynamics in children with spinal muscle atrophy (SMA) type II. Sleep Med. 2010;11(2):201–4.
Schroth MK. Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics. 2009;123 Suppl 4(Supplement 4):S245-9.
Gilgoff IS, Kahlstrom E, MacLaughlin E, Keens TG. Long-term ventilatory support in spinal muscular atrophy. J Pediatr. 1989;115(6):904–9.
Iannaccone ST. Modern management of spinal muscular atrophy. J Child Neurol. 2007;22(8):974–8.
Durkin ET, Schroth MK, Helin M, Shaaban AF. Early laparoscopic fundoplication and gastrostomy in infants with spinal muscular atrophy type I. J Pediatr Surg. 2008;43(11):2031–7.
Sproule DM, Montes J, Montgomery M, et al. Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. Neuromuscul Disord. 2009;19(6):391–6.
Kinali M, Banks LM, Mercuri E, Manzur AY, Muntoni F. Bone mineral density in a paediatric spinal muscular atrophy population. Neuropediatrics. 2004;35(6):325–8.
Fujak A, Kopschina C, Gras F, Forst R, Forst J. Contractures of the lower extremities in spinal muscular atrophy type II. Descriptive clinical study with retrospective data collection. Ortop Traumatol Rehabil. 2011;13(1):27–36.
Fujak A, Ingenhorst A, Heuser K, Forst R, Forst J. Treatment of scoliosis in intermediate spinal muscular atrophy (SMA type II) in childhood. Ortop Traumatol Rehabil. 2005;7(2):175–9.
Rudnik-Schöneborn S, Sztriha L, Aithala GR, et al. Extended phenotype of pontocerebellar hypoplasia with infantile spinal muscular atrophy: Extended Phenotype of PCH-1. Am J Med Genet A. 2003;117A(1):10–7.
Renbaum P, Kellerman E, Jaron R, et al. Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene. Am J Hum Genet. 2009;85(2):281–9.
Rudnik-Schöneborn S, Senderek J, Jen JC, et al. Pontocerebellar hypoplasia type 1: clinical spectrum and relevance of EXOSC3 mutations. Neurology. 2013;80(5):438–46.
Halevy A, Lerer I, Cohen R, et al. Novel EXOSC3 mutation causes complicated hereditary spastic paraplegia. J Neurol. 2014;261(11):2165–9.
Boczonadi V, Müller JS, Pyle A, et al. EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia. Nat Commun. 2014;5:4287.
Yildiz EP, Yesil G, Bektas G, et al. Spinal muscular atrophy with progressive myoclonic epilepsy linked to mutations in ASAH1. Clin Neurol Neurosurg. 2018;164:47–9.
Topaloglu H, Melki J. Spinal muscular atrophy associated with progressive myoclonus epilepsy. Epileptic Disord. 2016;18(S2):128–34.
Rubboli G, Veggiotti P, Pini A, et al. Spinal muscular atrophy associated with progressive myoclonic epilepsy: A rare condition caused by mutations in ASAH1. Epilepsia. 2015;56(5):692–8.
Chen Y, Xu Y, Li G, Li N, Yu T, Yao R-E, et al. Exome sequencing identifies DE Novo DYNC1H1 mutations associated with distal spinal muscular atrophy and malformations of cortical development. J Child Neurol. 2017;32(4):379–86.
Amabile S, Jeffries L, McGrath JM, et al. DYNC1H1-related disorders: A description of four new unrelated patients and a comprehensive review of previously reported variants. Am J Med Genet A. 2020;182(9):2049–57.
Storbeck M, Horsberg Eriksen B, Unger A, et al. Phenotypic extremes of BICD2-opathies: from lethal, congenital muscular atrophy with arthrogryposis to asymptomatic with subclinical features. Eur J Hum Genet. 2017;25(9):1040–8.
Koboldt DC, Waldrop MA, Wilson RK, Flanigan KM. The genotypic and phenotypic spectrum of BICD2 variants in spinal muscular atrophy. Ann Neurol. 2020;87(4):487–96.
Biasini F, Portaro S, Mazzeo A, et al. TRPV4 related scapuloperoneal spinal muscular atrophy: Report of an Italian family and review of the literature. Neuromuscul Disord. 2016;26(4–5):312–5.
Auer-Grumbach M, Olschewski A, Papić L, et al. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet. 2010;42(2):160–4.
Knierim E, Hirata H, Wolf NI, et al. Mutations in subunits of the activating signal cointegrator 1 complex are associated with prenatal spinal muscular atrophy and congenital bone fractures. Am J Hum Genet. 2016;98(3):473–89.
Wang XH, Zhang LM, Yang X, Zhou SZ. A pathogenic missense variant (c.1617G>A, p.Met539Ile) in UBA1 causing infantile X-linked spinal muscular atrophy (SMAX2). Front Pediatr. 2020;8:64.
Ramser J, Ahearn ME, Lenski C, et al. Rare missense and synonymous variants in UBA1 are associated with X-linked infantile spinal muscular atrophy. Am J Hum Genet. 2008;82(1):188–93.
Vuopala K, Ignatius J, Herva R. Lethal arthrogryposis with anterior horn cell disease. Hum Pathol. 1995;26(1):12–9.
Nousiainen HO, Kestilä M, Pakkasjärvi N, et al. Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease. Nat Genet. 2008;40(2):155–7.
Jaksch M, Horvath R, Horn N. Homozygosity (E140K)in SCO2causes delayedinfantile onset of cardiomyopathy and neuropathy. Neurology. 2001;57(8):1440– 1446.
Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE, et al. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nat Genet. 1999;23(3):333–7.
Mancuso M, Ferraris S, Pancrudo J, Feigenbaum A, Raiman J, Christodoulou J, et al. New DGK gene mutations in the hepatocerebral form of mitochondrial DNA depletion syndrome. Arch Neurol. 2005;62(5):745–7.
Mancuso M, Salviati L, Sacconi S, et al. Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology. 2002;59(8):1197–202.
Jaeger B, Bosch AM. Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience. J Inherit Metab Dis. 2016;39(4):559–64.
O’Callaghan B, Bosch AM, Houlden H. An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency. J Inherit Metab Dis. 2019;42(4):598–607.
Manole A, Jaunmuktane Z, Hargreaves I, et al. Clinical, pathological and functional characterization of riboflavin-responsive neuropathy. Brain. 2017;140(11):2820–37.
Elektronik veri tabanı: https://www.omim.org (Temmuz 2021).
Saladini M, Nizzardo M, Govoni A, et al. Spinal muscular atrophy with respiratory distress type 1: Clinical phenotypes, molecular pathogenesis and therapeutic insights. J Cell Mol Med. 2020;24(2):1169–78.
Jędrzejowska M, Madej-Pilarczyk A, Fidziańska A, et al. Severe phenotypes of SMARD1 associated with novel mutations of the IGHMBP2 gene and nuclear degeneration of muscle and Schwann cells. Eur J Paediatr Neurol. 2014;18(2):183–92.
Luan X, Huang X, Liu X, Zhou H, Chen S, Cao L. Infantile spinal muscular atrophy with respiratory distress type I presenting without respiratory involvement: Novel mutations and review of the literature. Brain Dev. 2016;38(7):685–9.
Yuan J-H, Hashiguchi A, Yoshimura A, et al. Clinical diversity caused by novel IGHMBP2 variants. J Hum Genet. 2017;62(6):599–604.
Ververis A, Dajani R, Koutsou P, et al. Distal hereditary motor neuronopathy of the Jerash type is caused by a novel SIGMAR1 c.500A>T missense mutation. J Med Genet. 2020;57(3):178–86.
Maystadt I, Rezsöhazy R, Barkats M, et al. The nuclear factor kappaB-activator gene PLEKHG5 is mutated in a form of autosomal recessive lower motor neuron disease with childhood onset. Am J Hum Genet. 2007;81(1):67–76.
Rossor AM, Kalmar B, Greensmith L, Reilly MM. The distal hereditary motorneuropathies. J Neurol Neurosurg Psychiatry. 2012;83(1):6-14.
Stögbauer F, KuhlenbÄumer G. Distal hereditary motor neuropathies (dHMN). In: Hereditary Peripheral Neuropathies. Darmstadt: Steinkopff-Verlag; 2005. p. 146–56.
Antonellis A, Ellsworth RE, Sambuughin N, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet. 2003;72(5):1293–9.
Windpassinger C, Auer-Grumbach M, Irobi J, et al. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet. 2004;36(3):271–6.
Beetz C, Pieber TR, Hertel N, et al. Exome sequencing identifies a REEP1 mutation involved in distal hereditary motor neuropathy type V. Am J Hum Genet. 2012;91(1):139–45.
Ingram G, Barwick KES, Hartley L, et al. Distal hereditary motor neuropathy with vocal cord paresis: from difficulty in choral singing to a molecular genetic diagnosis. Pract Neurol. 2016;16(3):247–51.
Auer-Grumbach M, Olschewski A, Papić L, et al. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet. 2010;42(2):160–4.
Tsai P-C, Soong B-W, Mademan I, et al. A recurrent WARS mutation is a novel cause of autosomal dominant distal hereditary motor neuropathy. Brain. 2017;140(5):1252–66.
Altuame FD, Foskett G, Atwal PS, et al. The natural history of infantile neuroaxonal dystrophy. Orphanet J Rare Dis. 2020;15(1):109.
Ramaekers VT, Lake BD, Harding B, et al. Diagnostic difficulties in infantile neuroaxonal dystrophy. A clinicopathological study of eight cases. Neuropediatrics. 1987;18(3):170–5.
Pierson TM, Torres PA, Zeng B-J, et al. Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidase. Mol Genet Metab. 2013;108(1):65–9.
Gitiaux C, Chemaly N, Quijano-Roy S, et al. Motor neuropathy contributes to crouching in patients with Dravet syndrome. Neurology. 2016;87(3):277–81.
Sferra A, Baillat G, Rizza T, , et al. TBCE mutations cause early-onset progressive encephalopathy with distal spinal muscular atrophy. Am J Hum Genet. 2016;99(4):974–83.
Rabin BA, Griffin JW, Crain BJ, Scavina M, Chance PF, Cornblath DR. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain. 1999;122(8):1539–50.
Hamida MB, Hentati F, Hamida CB. Hereditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis). Conditions combining a bilateral pyramidal syndrome with limb and bulbar amyotrophy. Brain. 1990;113(2):347–363,
Yang Y, Hentati A, Deng HX, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 20031;29(2):160–5.
Sheerin U-M, Schneider SA, Carr L, et al. ALS2 mutations: juvenile amyotrophic lateral sclerosis and generalized dystonia. Neurology. 2014;82(12):1065–7.
Kress JA, Kühnlein P, Winter P, , et al. Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis. Ann Neurol. 2005;58(5):800–3.
Chen Y-Z, Bennett CL, Huynh HM, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74(6):1128–35.
B. A. Rabin, J. W. Griffin, B. J. Crain, M. Scavina, P. F. Chance, and D. R. Cornblath, Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain. 1999;122(8):1539–50.
Jonghe PD, Auer-Grumbach M, Irobi J. Autosomal dominant juvenile amyotrophic lateral sclerosis and distal hereditary motor neuronopathy with pyramidal tract signs: synonyms for the same disorder? Brain. 2002;125, Part 6:1320–1325.
Orlacchio A, Babalini C, Borreca A, et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain. 2010;133(Pt 2):591–8.
Hamida MB, F. Hentati. Juvenile amyotrophic lateral sclerosis and related syndromes. Advances in Neurology. 1991;56:175-9.
Zou Z-Y, Liu M-S, Li X-G, Cui L-Y. Mutations in SOD1 and FUS caused juvenile-onset sporadic amyotrophic lateral sclerosis with aggressive progression. Ann Transl Med. 2015;3(15):221.
Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205–8.
Conte A, Lattante S, Zollino M, et al. P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul Disord. 2012;22(1):73–5.
Yan J, Deng H-X, Siddique N, Fecto F, Chen W, Yang Y, et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology. 2010;75(9):807–14.
Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol. 2011;70(6):913–9.
Hassan KM, Sahni H. Nosology of juvenile muscular atrophy of distal upper extremity: from monomelic amyotrophy to Hirayama disease--Indian perspective. Biomed Res Int. 2013;2013:478516.
Murphy OC, Messacar K, Benson L, et al. Acute flaccid myelitis: cause, diagnosis, and management. Lancet. 2021;397(10271):334–46.
Helfferich J, Knoester M, Van Leer-Buter CC, et al. Acute flaccid myelitis and enterovirus D68: lessons from the past and present. Eur J Pediatr. 2019;178(9):1305–15.
Vargas MI, Gariani J, Sztajzel R, Barnaure-Nachbar I, Delattre BM, Lovblad KO, Dietemann JL. Spinal cord ischemia: practical imaging tips, pearls, and pitfalls. AJNR Am J Neuroradiol. 2015 May;36(5):825-30.
Abhinav K, Al-Chalabi A, Hortobagyi T, Leigh PN. Electrical injury and amyotrophic lateral sclerosis: a systematic review of the literature. J Neurol Neurosurg Psychiatry. 2007;78(5):450-3
